A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia

Exclusion Criteria

• •Patients determined to require emergency treatment for hyperkalemia at the Run-in period baseline
• •Patients with poorly controlled blood pressure
• •Patients with heart failure in New York Heart Association Class IV
• •Patients who have experienced heart transplant, liver transplant or kidney transplant or who are predicted that the need for them will occur during the study
• •Patients who have taken any of the following medication within 7 days prior to the Run-in period baseline or currently administrated.
• •1. Sodium polystyrene sulfonate
• •2. Calcium polystyrene sulfonate
• •3. Sodium zirconium cyclosilicate hydrate
• •4. Potassium supplement
• •Patients with or who have experienced a severe swallowing disorder, moderate to severe gastroparesis, severe constipation, bowel obstruction, incarceration, abnormal post-operative bowel motility disorders or severe gastrointestinal disorders. In addition, patients who have experienced bariatric surgery or major gastrointestinal surgery (e.g., bowel resection).
• •Patients suspected to be with transient high potassium value.(ex. caused by dietary effects only)